期刊
ONCOTARGET
卷 7, 期 41, 页码 66809-66821出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.11631
关键词
endometrial cancer; JQ1; BRD4 inhibitor; PTEN/PI3K/AKT signal pathway; intrinsic resistance
资金
- Steelman Fund
- (UNC Clinical Translational Science Award-K12 Scholars Program) from the National Center for Research Resources [KL2RR025746]
- NIH/NCI K23 Mentored Patient-Oriented Research Career Development Grant [1K23CA143154-01A1]
- National Natural Science Funds of China [81502261]
- Postdoctoral Science Foundation of China [2015M570634]
- Henan Provincial Health and Family Planning Commission [201503009]
Overexpression of c-Myc is associated with worse outcomes in endometrial cancer, indicating that c-Myc may be a promising target for endometrial cancer therapy. A novel small molecule, JQ1, has been shown to block BRD4 resulting in inhibition of c-Myc expression and tumor growth. Thus, we investigated whether JQ1 can inhibit endometrial cancer growth in cell culture and xenograft models. In PTEN-positive endometrial cancer cells, JQ1 significantly suppressed cell proliferation via induction of G1 phase arrest and apoptosis in a dose-dependent manner, accompanied by a sharp decline in cyclin D1 and CDK4 protein expression. However, PTEN-negative endometrial cancer cells exhibited intrinsic resistance to JQ1, despite significant c-Myc inhibition. Moreover, we found that PTEN and its downstream PI3K/AKT signaling targets were modulated by JQ1, as evidenced by microarray analysis. Silencing of PTEN in PTEN-positive endometrial cancer cells resulted in resistance to JQ1, while upregulation of PTEN in PTEN-negative endometrial cancer cells increased sensitivity to JQ1. In xenografts models of PTEN-positive and PTEN-knock-in endometrial cancer, JQ1 significantly upregulated the expression of PTEN, blocked the PI3K/AKT signaling pathway and suppressed tumor growth. These effects were attenuated in PTEN-negative and PTEN-knockdown xenograft models. Thus, JQ1 resistance appears to be highly associated with the status of PTEN expression in endometrial cancer. Our findings suggest that targeting BRD4 using JQ1 might serve as a novel therapeutic strategy in PTEN-positive endometrial cancers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据